Description: This paper discussed providing consumers of medical care with transparent and comparable price and quality information to enable them to make economically optimal decisions.

Description: This session discusses what will happen to supplemental coverages under health care reform. Topics include traditional group ancillary benefits, health care reform supplements, and traditional individual/group niche products? From Record of Society of Actuaries Vol. 20, No. 3A.

Description: A discussion by several experts of reform activity at the state level will be included. What can be learned from reforms to date? What is likely to happen in the near term? From the Record of the Society of Actuaries, Vol. 21, No. 3b.

Description: States can make ACA markets more attractive by enforcing compliance. Unlike other state opportunities, it doesn't cost anything. Pennsylvania made the change this year.

Description: This session dealt with Regulatory Considerations in Group Insurance. Topics included: 1. National health insurance. 2. Federal hospital cost control programs. 3. Non-discrimination legislation and regulation. 4. Multiple- employer trusts. 5. Impact of recent OASDI financing changes. 6. Changes in mandatory retirement age on group insurance.

Description: This session is about the impact of health-care reform on supplemental health insurance plans such as Medicare Supplement, Hospital, Cancer, etc. The session will also explore new opportunities for supplementary markets and products. Included is a discussion of the CHAMPUS and FEHBP. From Record of Society of Actuaries Vol. 19, No. 4B.

Description: 2001 SOA Annual Meeting, New Orleans. Health care cost trends have substantially increased in the past two years. Panelists discussed the factors contributing to these increased trends, the prospect for further increases in the future, and national health care issues.

Description: Panelists at this session of the SOA 2000 Las Vegas Spring Meeting discuss the roles of the federal and state governments in regulating health care insurance, the potential overlaps of these jurisdictions, and how insurance companies, health plans, and providers are being affected.

Description: The big event of 2023 is the launch of multiple Humira biosimilars, which began in January with the arrival of Amgen’s Amjevita on the market. The launch of Amjevita kicks off the process of changing the specialty drug marketplace in the United States. The expectation of the full impact of this big event is very hopeful, but there is still uncertainty several months after its beginning. Humira is the highest-selling drug in the world and has been since 2013 (Figure 1)—except for when COVID-19 projects temporarily surpassed it. The world is eagerly awaiting the launch of multiple biosimilar drugs to compete with Humira and hopefully bring more competitive pricing to the benefit of payers and patients everywhere.

Description: This essay discusses the long overdue effciencies that would improve the quality of healthcare in the United States.